• Global drug spending to hit $1.4 trillion in 2020: IMS

    Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will

  • Lessons from Australia and China’s Healthcare Cooperation: What Can Canadian Firms Learn?

    NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit

  • South Korea's Genexine expands into China in Tasgen deal for up to $100M

    South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i

Investment Opportunities


Potash in another mining friendly region other than Saskatchewan

With the junior mining sector struggling in the past few years, it is difficult for inv... Full Story

The hidden gems in CSE

Breaking News

China updates key drug list in boost for Big Pharma

China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world's second-largest drug market where many new drugs hav...

Fudan-Zhangjiang Bio-Pharma Invests $2 Million in Adgero of the US

Matrix Joins $28M Series B In Chinese App For Children And Women's Healthcare

Hong Kong's Ally Bridge Invests in Two European Biopharmas

BioSense Inks $68 Million Deal for Neovacs’ Autoimmune Disease Vaccine in China

Select Companies

CohBar, Inc.

CohBar is an innovator and leader in the research and development of mitochondria-based therapeut...

Naturally Splendid Enterprises Ltd

Race Capital Corp is a Capital Pool Company. The principal business of the Company is the identif...

Replicel Life Sciences Inc

Replicel Life Sciences Inc is a clinical stage bio-pharmaceutical company engaged in developing a...

Experts Column

Top 10 Developments that Investors should pay extra attention in the new year

Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...

China could boost growth with supply, property reforms, tax cuts, HSBC says

China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...

Here’s how to play Chinese stocks in 2016?

Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...

G-20 sticks to 2% growth goal despite headwinds

The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...

Why isn't the yuan rising despite IMF support?

The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...

Press Release

RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement

, a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that it has completed its financing announced on February ...

Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial

today announced the receipt of the final minutes of an in-person Type B meeting with the Cardiovascular and Renal Products Division of the U.S. Food and Drug Administration (FDA). The pur...

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

, a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it has completed a study to ev...

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results

Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease

CohBar, Inc.’s CEO Simon Allen to Present at the 2017 BIO CEO & Investor Conference in New York

RepliCel Announces European Patents for its Innovative Dermal Injector Technologies

Daily Top Performing Life Science Stocks
         Company Name Symbol Price Change Vol(k) Day's Range Contact
1 IntelliPharmaCeutics International Inc NASDAQ:IPCI 2.550
0.400 (18.60%)
5525503 2.50 - 2.82
2 GeneNews Ltd TSX:GEN 0.350
0.050 (16.67%)
900869 0.29 - 0.35
3 Aurinia Pharmaceuticals Inc TSX:AUP 4.880
0.610 (14.29%)
129017 4.29 - 4.90
4 Digirad Corp NASDAQ:DRAD 5.250
0.470 (9.95%)
172830 4.90 - 5.25
5 Alphatec Holdings Inc NASDAQ:ATEC 3.550
0.280 (8.56%)
97699 3.25 - 3.65
6 Galectin Therapeutics Inc NASDAQ:GALT 1.900
0.120 (6.60%)
366007 1.72 - 1.90
7 TG Therapeutics Inc NASDAQ:TGTX 5.900
0.300 (5.36%)
657601 5.50 - 6.00
8 Ocera Therapeutics Inc NASDAQ:OCRX 0.629
0.029 (4.75%)
673220 0.5812 - 0.6285
9 TearLab Corp NASDAQ:TEAR 0.525
0.022 (4.31%)
232198 0.4551 - 0.5390
10 Retractable Technologies Inc NYSE MKT:RVP 1.070
0.030 (2.88%)
48159 1.01 - 1.07
11 RTI Surgical Inc NASDAQ:RTIX 3.600
0.100 (2.86%)
180816 3.45 - 3.70
12 Conatus Pharmaceuticals Inc NASDAQ:CNAT 4.950
0.130 (2.70%)
130754 4.75 - 4.96
13 Trimel Pharmaceuticals Corp TSX:TRL 9.750
0.250 (2.63%)
200 9.75 - 9.83
14 Alimera Sciences Inc NASDAQ:ALIM 1.260
0.030 (2.44%)
540917 1.16 - 1.26
15 Sunesis Pharmaceuticals Inc NASDAQ:SNSS 4.290
0.100 (2.39%)
62655 4.11 - 4.33